Literature DB >> 22359721

Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Zeina A Al-Thanoon1, Isam H Mahmood.   

Abstract

OBJECTIVE: To compare the effects of losartan and enalapril on the markers of metabolic syndrome.
METHODS: One hundred and twenty six newly diagnosed hypertensive patients having other markers of metabolic syndrome participated in this study. The study was performed in the department of pharmacology, college of medicine at Ibn-Sina Teaching Hospital in Mosul city, Iraq, during the period between December 2007 and June 2009. The patients were divided into 2 main groups: 1) Losartan group: consisted of 60 patients, and 2) enalapril group: Consisted of 66 patients. Waist circumference, weight, Body mass index, blood pressure, serum glucose concentration, triglyceride and HDL-cholestrol were measured before and after administration of therapy. The effects of therapy were assessed by statistically comparing the results before and after the drug administration.
RESULTS: Comparison of waist circumference, blood pressure, FSG, triglycerides of the patients before drug administration (baseline data), with those of the controls showed a significant elevation, while HDL-cholesterol showed a significant reduction. A significant reduction of waist circumference, BP, FSG and a significant elevation of HDL-cholesterol were also noted after therapy with both losartan and enalapril.
CONCLUSION: Both losartan and enalapril produced a significant reduction of markers of metabolic syndrome and may be regarded as effective drugs for treatment of hypertension in patients with markers of metabolic syndrome.

Entities:  

Keywords:  Enalapril; Hypertension; Losartan; Metabolic syndrome

Year:  2012        PMID: 22359721      PMCID: PMC3282135          DOI: 10.5001/omj.2012.05

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  33 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

2.  Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.

Authors:  E J Henriksen; S Jacob; T R Kinnick; M K Teachey; M Krekler
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

3.  Evaluation of Trinder's glucose oxidase method for measuring glucose in serum and urine.

Authors:  J A Lott; K Turner
Journal:  Clin Chem       Date:  1975-11       Impact factor: 8.327

Review 4.  The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?

Authors:  Asterios Karagiannis; Dimitri P Mikhailidis; Vasilios G Athyros; Anna I Kakafika; Konstantinos Tziomalos; Evangelos N Liberopoulos; Matilda Florentin; Moses Elisaf
Journal:  Expert Opin Ther Targets       Date:  2007-02       Impact factor: 6.902

Review 5.  The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

Authors:  Stefan Engeli; Petra Schling; Kerstin Gorzelniak; Michael Boschmann; Jürgen Janke; Gérard Ailhaud; Michèle Teboul; Florence Massiéra; Arya M Sharma
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

6.  ACE, angiotensinogen and obesity: a potential pathway leading to hypertension.

Authors:  R Cooper; N McFarlane-Anderson; F I Bennett; R Wilks; A Puras; D Tewksbury; R Ward; T Forrester
Journal:  J Hum Hypertens       Date:  1997-02       Impact factor: 3.012

7.  The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield
Journal:  Arch Intern Med       Date:  2003-02-24

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 9.  Impact of the renin-angiotensin system on lipid and carbohydrate metabolism.

Authors:  Pasquale Strazzullo; Ferruccio Galletti
Journal:  Curr Opin Nephrol Hypertens       Date:  2004-05       Impact factor: 2.894

10.  Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.

Authors:  R Townsend; B Haggert; C Liss; J M Edelman
Journal:  Clin Ther       Date:  1995 Sep-Oct       Impact factor: 3.393

View more
  5 in total

1.  Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome.

Authors:  Michael S Kostapano; Niki Katsiki; Vasilios G Athyros; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Oman Med J       Date:  2012-03

2.  Prevalence of Metabolic Syndrome in Patients with Schizophrenia Referred to Farabi Hospital, Kermanshah, Iran.

Authors:  Jalal Shakeri; Kamyar Karimi; Vahid Farnia; Senobar Golshani; Mostafa Alikhani
Journal:  Oman Med J       Date:  2016-07

3.  A Study to Assess the Therapeutic Effect of Enalapril on Olanzapine Induced Metabolic Syndrome in Wistar Rats.

Authors:  Avinash Arivazhahan; Laxminarayana Kurady Bairy; Veena Nayak; Sushil Kiran Kunder
Journal:  J Clin Diagn Res       Date:  2017-02-01

Review 4.  The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration.

Authors:  Rebecca Hutcheson; Petra Rocic
Journal:  Exp Diabetes Res       Date:  2012-07-09

Review 5.  Medications that cause weight gain and alternatives in Canada: a narrative review.

Authors:  Sean Wharton; Lilian Raiber; Kristin J Serodio; Jasmine Lee; Rebecca Ag Christensen
Journal:  Diabetes Metab Syndr Obes       Date:  2018-08-21       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.